Householder Group Estate & Retirement Specialist LLC Sells 5,421 Shares of Johnson & Johnson (NYSE:JNJ)

Householder Group Estate & Retirement Specialist LLC reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 89.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 612 shares of the company's stock after selling 5,421 shares during the period. Householder Group Estate & Retirement Specialist LLC's holdings in Johnson & Johnson were worth $88,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. Highline Wealth Partners LLC acquired a new position in Johnson & Johnson during the third quarter valued at $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Activest Wealth Management purchased a new position in Johnson & Johnson during the third quarter valued at approximately $40,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on JNJ. Wells Fargo & Company boosted their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a report on Wednesday, October 16th. Citigroup dropped their target price on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research report on Wednesday, December 11th. Guggenheim boosted their price target on Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. Royal Bank of Canada raised their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Finally, Wolfe Research began coverage on shares of Johnson & Johnson in a research report on Friday, November 15th. They issued an "outperform" rating and a $190.00 target price for the company. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.29.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded down $0.74 during trading hours on Friday, hitting $147.03. 10,678,393 shares of the company's stock were exchanged, compared to its average volume of 6,880,262. The stock has a market capitalization of $353.99 billion, a price-to-earnings ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The company's 50-day moving average price is $148.51 and its 200-day moving average price is $156.03. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is currently 71.78%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.